Meet-the-Professor Session:
103. Controversies in Empiric and Definitive Treatment of ESBL Infections
Friday, October 6, 2017: 7:00 AM-8:15 AM
Room: 16AB

Learning Objectives:

At the conclusion of this session, participants will be able to:

  • identify controversies in the treatment of ESBL infections.
  • describe the evidence for active empiric therapy for ESBL infections.
  • describe the evidence for what antibiotics should be used for definitive therapy when an ESBL infection has been identified.

Target Audience: Academicians, Clinicians, Fellows, Healthcare workers, Infectious diseases pediatricians, Infectious diseases physicians, Medical students and residents, Members-in-training, Pharmacists

Tracks: Pediatric ID, Adult ID, Trainee


Moderator:  David Greenberg, MD, FIDSA, University of Texas Southwestern Medical Center

Presentations:
8:00 AM
Q&A

CME Credits: Maximum of 1.25 hours of AMA PRA Category 1 Credit™

ACPE Credits: ACPE 1.25 knowledge-based contact hours of pharmacy CE

ACPE Number: 0221-9999-17-258-L01-P

Disclosures:

D. Greenberg, Accelerate Diagnostics: Consultant and Scientific Advisor , Consulting fee
Boston Pharmaceuticals: Consultant and Scientific Advisor , Consulting fee
Sarepta: Patent, Copyright, License , Licensing agreement or royalty

Findings in the abstracts are embargoed until 12:01 a.m. PDT, Wednesday Oct. 4th with the exception of research findings presented at the IDWeek press conferences.